Study guide

4.1 Alcohol Withdrawal Syndrome Management & Complication Prevention

Certified Addictions Registered Nurse CARN

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Overview

1.1 CARN Exam Overview, Eligibility & Requirements 1.2 How to Use This Study Guide & Preparation Strategy

2 Chapter 2: Assessment & Screening

2.1 DSM-5-TR Substance Use Disorder Diagnostic Criteria & Severity Classification 2.2 Standardized Screening Tools: AUDIT, DAST-10, CAGE, CRAFFT & ASSIST 2.3 Withdrawal Severity Rating Scales: CIWA-Ar & COWS 2.4 Neonatal & Special Population Assessment: Finnegan, Eat-Sleep-Console & Life Stages 2.5 Assessment of Co-Occurring Psychiatric & Medical Disorders

3 Chapter 3: Planning & Intervention

3.1 ASAM Criteria & Continuum of Placement Care 3.2 Motivational Interviewing (OARS) & Transtheoretical Stages of Change 3.3 Trauma-Informed Care Principles & Addictions Nursing Practice 3.4 Family Dynamics, Codependency, CRAFT Model & Family Support Systems 3.5 Nursing Diagnosis, Outcome Identification & Individualized Addictions Care Planning

4 Chapter 4: Clinical Management & Pharmacotherapy

4.1 Alcohol Withdrawal Syndrome Management & Complication Prevention 4.2 Opioid Withdrawal Management & Symptom-Triggered Protocols 4.3 Medications for Opioid Use Disorder (MOUD: Methadone, Buprenorphine & Extended-Release Naltrexone) 4.4 Pharmacotherapy for Alcohol & Nicotine Use Disorders 4.5 Harm Reduction Strategies: Naloxone, Fentanyl Test Strips & Syringe Services 4.6 Pain Management in Patients with Substance Use Disorders

5 Chapter 5: Substance-Specific Disorders, Prevention & Patient Education

5.1 Stimulant Use Disorders: Cocaine, Amphetamines & Caffeine 5.2 Sedative, Hypnotic, Anxiolytic & Gabapentinoid Misuse 5.3 Cannabis & Hallucinogen Use Disorders 5.4 Tobacco Use Disorder, Vaping & Cessation Interventions 5.5 Prevention, Brief Intervention, Patient Education & Behavioral Addictions

6 Chapter 6: Evaluation, Recovery & Continuing Care

6.1 Relapse Prevention Models: Marlatt's Model, Urge Surfing & High-Risk Situations 6.2 Mutual-Help Groups & Peer Recovery Support: 12-Step, SMART Recovery & Peer Specialists 6.3 Recovery Capital, Social Determinants of Health & Holistic Wellness 6.4 Transitions of Care, Discharge Planning & Long-Term Recovery Management

7 Chapter 7: Professional Role, Ethics & Legal Issues

7.1 ANA/IntNSA Scope & Standards of Addictions Nursing Practice 7.2 Confidentiality Laws: 42 CFR Part 2 vs. HIPAA & 2024 Alignment Updates 7.3 Legal & Ethical Issues, Stigma Reduction & Person-First Language

4.1 Alcohol Withdrawal Syndrome Management & Complication Prevention

Key Takeaways Explain This Topic AI

The Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar) evaluates 10 items (maximum score 67); scores <8 indicate mild withdrawal, 8–14 moderate, and ≥15 severe withdrawal requiring symptom-triggered benzodiazepines (e.g., chlordiazepoxide 25–100 mg, diazepam 10–20 mg, or lorazepam 1–4 mg).

High-dose thiamine (vitamin B1) 100–500 mg IV must ALWAYS be administered PRIOR to dextrose-containing IV fluids to prevent precipitating acute Wernicke's Encephalopathy (classic triad: global confusion, ataxia, and ophthalmoplegia).

Delirium Tremens (DTs) is a life-threatening medical emergency characterized by profound disorientation, severe agitation, visual/auditory hallucinations, and hyperadrenergic autonomic surge, typically developing 48–96 hours after abrupt cessation of heavy alcohol use.

Symptom-triggered benzodiazepine administration protocol significantly reduces total benzodiazepine requirement, shortens duration of treatment, and lowers over-sedation risk compared to fixed-schedule dosing regimens.

Lorazepam, oxazepam, or temazepam (the LOT agents) are preferred in patients with severe hepatic impairment, advanced age, or acute respiratory compromise because they undergo direct glucuronidation without active hepatic cytochrome P450 metabolites.

Last updated: August 2026

  • Alcohol Withdrawal Syndrome Management & Complication Prevention
  • Neurobiology of Alcohol Withdrawal

Alcohol (ethanol) acts as a central nervous system (CNS) depressant primarily through two complementary neurochemical mechanisms: enhancing gamma-aminobutyric acid (GABA) receptor activity (the primary inhibitory neurotransmitter in the brain) and inhibiting N-methyl-D-aspartate (NMDA) glutamate receptors (the primary excitatory neurotransmitter). Chronic, heavy alcohol consumption induces profound neuroadaptation. To compensate for continuous alcohol-induced inhibition, the brain down-regulates GABA-A receptor sensitivity and up-regulates NMDA receptor density and responsiveness.

When alcohol consumption is abruptly reduced or stopped, the loss of exogenous GABAergic enhancement coupled with uninhibited NMDA glutamate receptor overactivity leads to a severe CNS hyperexcitability state known as Alcohol Withdrawal Syndrome (AWS) . Uncontrolled glutamate-mediated excitotoxicity and noradrenergic hyperactivity drive the clinical manifestations of withdrawal, ranging from mild autonomic tremors to life-threatening seizures and delirium tremens.

Clinical Manifestations & Temporal Progression

Alcohol withdrawal follows a characteristic temporal progression based on the time elapsed since the patient's last alcohol drink. Certified Addictions Registered Nurses (CARN) must anticipate symptom onset to initiate timely prophylaxis.

6 to 12 Hours (Minor Withdrawal Symptoms): Tremulousness ("shakes"), mild diaphoresis, tachycardia (HR >100 bpm), hypertension, anxiety, headache, insomnia, anorexia, and mild gastrointestinal upset. Sensorium remains clear.

12 to 24 Hours (Alcoholic Hallucinosis): Visual, auditory, or tactile hallucinations (e.g., feeling insects crawling on skin—formication). Importantly, alcoholic hallucinosis occurs in a clear sensorium (the patient is oriented), distinguishing it from delirium tremens.

24 to 48 Hours (Withdrawal Seizures): Generalized tonic-clonic seizures, often occurring as single or brief clustered paroxysms. If untreated, up to 33% of patients with withdrawal seizures progress to delirium tremens.

48 to 96 Hours (Delirium Tremens - DTs): Profound disorientation, fluctuating delirium, severe agitation, vivid hallucinations, fever, extreme diaphoresis, marked hypertension, and tachypnea. DTs carries a historical mortality rate of 5–15% if unrecognized.

CIWA-Ar Assessment & Protocol

The Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar) is the gold-standard, validated tool for quantifying alcohol withdrawal severity and guiding symptom-triggered pharmacotherapy. The scale evaluates 10 clinical items, with total scores ranging from 0 to 67 .

  • The 10 CIWA-Ar Evaluation Items
  • Nausea and Vomiting (Scored 0–7)
  • Tremor (Scored 0–7, assessed with arms extended and fingers spread)
  • Paroxysmal Sweats (Scored 0–7)
  • Anxiety (Scored 0–7)
  • Agitation (Scored 0–7)
  • Tactile Disturbances (Scored 0–7: itching, numbness, burning, formication)
  • Auditory Disturbances (Scored 0–7: harshness, loud noises, auditory hallucinations)
  • Visual Disturbances (Scored 0–7: light sensitivity, visual hallucinations)
  • Headache, Fullness in Head (Scored 0–7)
  • Orientation and Clouding of Sensorium (Scored 0–4: 0 = oriented; 4 = disoriented to place/person)
  • CIWA-Ar Severity Categories & Nursing Actions

Score < 8 (Mild Withdrawal): Supportive non-pharmacological nursing care, vital signs monitoring Q4H, re-evaluate CIWA-Ar Q4-8H. Benzodiazepines typically not required.

Score 8 to 14 (Moderate Withdrawal): Initiate symptom-triggered oral benzodiazepines. Monitor CIWA-Ar and vital signs Q2H.

Score ≥ 15 (Severe Withdrawal): Administer higher-dose symptom-triggered benzodiazepines immediately. Monitor CIWA-Ar and vital signs Q1H. Consider intensive care unit (ICU) transfer if score remains >20 despite aggressive dosing.

Safety Warning: CIWA-Ar requires patient participation. If a patient is uncommunicative, severely delirious, or stuporous, CIWA-Ar cannot be accurately scored; clinical judgment and objective vital signs (RASS score, heart rate, blood pressure) must guide therapy.

Benzodiazepine Pharmacotherapy (Symptom-Triggered vs. Fixed-Schedule)

Benzodiazepines are the first-line drug class for managing alcohol withdrawal because they act as positive allosteric modulators at GABA-A receptors, cross-substituting for alcohol and restoring central inhibitory tone.

Dosing Regimens

Symptom-Triggered Dosing (Preferred): Medication is administered ONLY when CIWA-Ar score reaches ≥8 or ≥10. This approach reduces overall medication dosage, decreases total duration of detoxification, avoids over-sedation, and allows individualization of care.

Fixed-Schedule Dosing: Prescribed doses are given at regular intervals (e.g., chlordiazepoxide 50 mg Q6H for 24h, then 25 mg Q6H for 24h) with additional breakthrough doses for elevated CIWA scores. Reserved for patients with a history of severe DTs/seizures, uncooperative patients, or settings without 24/7 nursing re-assessment.

Benzodiazepine Selection Matrix

Medication Half-Life & Metabolites Primary Indication Clinical Nursing Considerations

Chlordiazepoxide (Librium) Long-acting (t½ 24–100h); active hepatic metabolites Standard ambulatory & inpatient detox Smooth auto-tapering effect; low abuse potential; Avoid in severe hepatic dysfunction

Diazepam (Valium) Rapid onset; very long-acting (t½ 20–100h) Acute severe agitation, refractory DTs Rapid onset provides immediate relief; risk of cumulative accumulation in elderly/cirrhotic

Lorazepam (Ativan) Intermediate-acting (t½ 10–20h); no active metabolites Hepatic impairment , elderly, renal failure Direct glucuronidation ( LOT agent ); available PO, IV, IM; lower tissue accumulation risk

Oxazepam (Serax) Short-to-intermediate (t½ 5–15h); no active metabolites Mild-moderate detox in hepatic impairment Slow oral absorption; not suitable for acute severe delirium or rapid sedation

Prevention of Wernicke-Korsakoff Syndrome

Wernicke-Korsakoff Syndrome is a devastating neurological complication caused by severe thiamine (vitamin B1) deficiency, common in chronic alcohol dependence due to poor nutrition, impaired intestinal absorption, and reduced hepatic storage.

Clinical Presentation

Wernicke's Encephalopathy (Acute Phase): Reversible triad of global confusion , ataxia (unsteady gait), and ophthalmoplegia (nystagmus, lateral rectus muscle paralysis).

Korsakoff's Psychosis (Chronic Phase): Irreversible neuro-psychiatric condition characterized by profound anterograde and retrograde amnesia, confabulation (fabricating memories to fill memory gaps), and apathy.

CRITICAL NURSING DIRECTIVE: High-dose thiamine (100–500 mg IV/IM) must ALWAYS be administered BEFORE or concurrently with intravenous dextrose solutions. Glucose administration in thiamine-deficient patients accelerates thiamine consumption during glycolysis, triggering rapid, irreversible brainstem lesions and acute Wernicke's encephalopathy.

Delirium Tremens (DTs) & Seizure Management

DTs is a medical emergency requiring intensive management. Severe agitation, fever, and diaphoresis cause extreme dehydration, electrolyte imbalances (hypokalemia, hypomagnesemia, hypophosphatemia), and rhabdomyolysis.

High-Yield Emergency Nursing Interventions

Aggressive IV Sedation: Titrate IV lorazepam or diazepam to achieve light sedation (RASS 0 to -1). High doses (e.g., diazepam 10–20 mg IV Q10–15min) may be required.

Refractory DTs Management: If high-dose benzodiazepines fail, add IV phenobarbital (barbiturate enhancing GABA duration) or propofol infusion in an ICU setting.

Magnesium & Electrolyte Repletion: Hypomagnesemia lowers seizure threshold and worsens cardiac dysrhythmias; administer IV magnesium sulfate as ordered.

Seizure Precautions: Padded side rails, suction equipment at bedside, airway management equipment ready. Note that routine antiepileptic drugs (e.g., phenytoin) are ineffective for alcohol withdrawal seizures.

Loading diagram... Alcohol Withdrawal Syndrome Timeline & Clinical Progression